Improvement of fibrosis is associated with the decrease of collagen III formation biomarker Pro-C3 in patients with non-alcoholic steatohepatitis

被引：0
|
作者：
Luo, Yi [1 ]
Vincent, Robert [2 ]
Gagnon, Robert C. [1 ]
Charles, Edgar D. [1 ]
Oseini, Abdul [2 ]
Mirshahi, Faridoddin [2 ]
Banini, Bubu A. [2 ]
Daita, Kalyani [2 ]
Idowu, Michael O. [2 ]
Rosen, Glenn D. [1 ]
Jarai, Gabor [1 ]
Christian, Rose [1 ]
Sanyal, Arun J. [2 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
633
引用
收藏
页码：345A / 345A
页数：1
相关论文
共 50 条
  • [31] PRO-C3 als Biomarker für LeberfibrosePro-C3 as a biomarker for liver fibrosis
    S. Kahl
    Der Diabetologe, 2021, 17 : 758 - 760
  • [32] Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis
    Eguchi, Akiko
    Du Jeu, Xavier De Mollerat
    Johnson, Casey D.
    Nektaria, Andronikou
    Feldstein, Ariel E.
    JOURNAL OF HEPATOLOGY, 2016, 64 (03) : 699 - 707
  • [33] Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study
    Honda, Y.
    Kessoku, T.
    Tomeno, W.
    Imajo, K.
    Yoneda, M.
    Saito, S.
    Nakahara, T.
    Ooeda, S.
    Takahashi, H.
    Hyogo, H.
    Eguchi, Y.
    Nakajima, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S831 - S831
  • [34] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, Sudeep
    Trembling, Paul M.
    Guha, Indra Neil
    Parkes, Julie
    Kaye, Philip
    Burt, Alastair D.
    Ryder, Stephen D.
    Aithal, Guruprasad P.
    Day, Christopher P.
    Rosenberg, William M.
    HEPATOLOGY, 2011, 54 : 1123A - 1123A
  • [35] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, S.
    Trembling, P.
    Guha, I. N.
    Parkes, J.
    Kaye, P.
    Burt, A. D.
    Ryder, S. D.
    Aithal, G. P.
    Day, C. P.
    Rosenberg, W. M.
    GUT, 2011, 60 : A4 - A5
  • [36] METABOLOMICS PROFILE OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS
    Younossi, Zobair M.
    Karrar, Azza
    Stepanova, Maria
    Lam, Brian P.
    Felix, Sean
    Jeffers, Thomas
    Hellings, Samuel
    Brown, Elizabeth
    Thompson, John
    Onorato, Joelle
    Reily, Michael
    Warrack, Bethanne
    Luo, Yi
    Zhelnin, Leonid
    Charles, Edgar D.
    Mukherjee, Sumanta
    Zhao, Lei
    Gordon, David
    Nader, Fatema
    Goodman, Zachary D.
    HEPATOLOGY, 2019, 70 : 1035A - 1036A
  • [37] ANALYSIS OF PRO-C3, A BIOMARKER OF LIVER FIBROSIS, IN CHILDREN WITH NAFLD AND HEALTHY CONTROLS
    Castillo-Leon, Eduardo
    Cioffi, Catherine
    Cleeton, Rebecca L.
    Farris, Alton B., III
    Leeming, Diana Julie
    Shevell, Diane
    Nielsen, Mette J.
    Vos, Miriam B.
    HEPATOLOGY, 2020, 72 : 873A - 873A
  • [38] PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C
    Hansen, Janne Fuglsang
    Nielsen, Mette Juul
    Nystrom, Kristina
    Leeming, Diana Julie
    Lagging, Martin
    Norkrans, Gunnar
    Christensen, Peer Brehm
    Karsdal, Morten
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (01) : 83 - 87
  • [39] Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C
    Nielsen, Mette J.
    Veidal, Sanne S.
    Karsdal, Morten A.
    Orsnes-Leeming, Diana J.
    Vainer, Ben
    Gardner, Stephen D.
    Hamatake, Robert
    Goodman, Zachary D.
    Schuppan, Detlef
    Patel, Keyur
    LIVER INTERNATIONAL, 2015, 35 (02) : 429 - 437
  • [40] Type III collagen pro-peptides (PRO-C3) as a proposed prognostic biomarker of risk of survival outcomes in clinical trials of patients with solid tumors
    Willumsen, Nicholas
    Nissen, Neel Ingemann
    Karsdal, Morten Asser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345